Print

Cyprotex (COTXF.PK) Officially Open New Toxicology Laboratory  
10/1/2010 12:08:29 PM

October 1, 2010 -- Today, David Rutley, MP for Macclesfield, will officially open Cyprotex’s new toxicology facility at its headquarters in Macclesfield, UK. The additional 90 square metres of laboratory space houses the very latest technology in multi-parametric automated fluorescent imaging and cellular analysis, a Thermo Scientific Cellomics ArrayScan® VTI High Content Screening Reader. This technology is considered to be a breakthrough in terms of in vitro toxicity testing as multiple markers of toxicity can be analysed in a single cell which improves sensitivity and prediction of toxic effect. It has been extensively validated, and is now being adopted throughout the pharmaceutical industry.

Cyprotex’s expansion into the toxicology market has been enhanced by its recent acquisition of US-based Apredica and Cellumen’s novel CellCiphrTM informatics platform and assets. As well as an additional four Cellomics High Content Screening instruments in the US, Cyprotex can now provide a powerful, and unrivalled, combination of in vitro ADME, in vitro toxicology and proprietary predictive technology.

Dr Anthony Baxter, Cyprotex’s Chief Executive Officer, comments on the launch of the new toxicology facility (branded as Cyprotox®).

‘We are delighted to officially launch our new venture. The event brings together everyone who made this happen from the contractors (P&A Services) who built the facility, the brand agency (Verve Brands) who helped us to design and market the new service, to the Cyprotex staff responsible for managing the process and validating the assays. The expansion would not have been possible without our customers and I would also like to thank them for their continued support and contribution in transforming Cyprotex into the successful business it is today.

Toxicity is a major reason for drug attrition and failure. It is reported that drug toxicity is responsible for approximately 30% of all drug failures in preclinical and clinical assessment. This has considerable cost implications for the pharmaceutical industry. Using in vitro techniques such as high content screening in the drug discovery process addresses this issue by identifying potential liabilities early and reducing the likelihood of late stage failure.’

For further information:

Cyprotex PLC Swadipa Das, Marketing Manager Tel: +44 (0)1625 505 100 s.das@cyprotex.com www.cyprotex.com

Mo Noonan Senior Manager Financial Communications

Holborn Gate, 26 Southampton Buildings London, WC2A 1PB T +44 (0)20 7269 7116 F +44 (0)20 7242 8676 M +44 (0)7876 444 977 www.fd.com

A member of FTI Consulting Inc.


//-->